INE935A01035
INE935A01035
GLENMARK PHARMACEUTICALS
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2026 | 2025 | Change % |
|---|---|---|---|
| Total Revenue | 167.114.030.000 | 131.458.360.000 | 27.1% |
| Cost of Revenue | 51.139.070.000 | 47.573.420.000 | 7.5% |
| Gross Profit | 115.974.960.000 | 83.884.940.000 | 38.3% |
| 75.741.700.000 | 65.200.270.000 | 16.2% | |
| Operating Income | 40.233.260.000 | 18.684.670.000 | 115.3% |
| Pretax Income | 19.847.460.000 | 13.992.090.000 | 41.8% |
| Net Income Common Stockholders | 13.618.510.000 | 10.470.970.000 | 30.1% |
| -- | -- | -- | |
| -- | -- | -- |